Helix Biopharma Corp. · TSX:HBP
Helix Biopharma — Investor Presentation (January 2026)
34 slides from Helix Biopharma's investor presentation, January 2026
Slide 1: Shaping a near future where today's hard-to-treat cancers are vincible
Shaping a near future where today’s hard-to-treat cancers are vincible. As featured in: (US Audiences Only) PUBLIC Company Presentation, January 2026
Slide 2: Patient testimonial on L-DOS47
“I am a stage 4 lung cancer patient and have been on L-DOS47 [with chemotherapy] since June of 2017. To date my tumor has shrunk by 99%! Early on in my diagnosis I was told I had maybe four months to live. I am now in remission, and looking forward to many years with my grandchildren.“ Patient email
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Helix BioPharma is on a mission to level the playing field against cancer’s biggest, most urgent challenges. INNOVATING FROM STRENGTH FOCUSED, AMBITIOUS PLAN AHEAD Assets with great potential and a head start Relocation to the US and NASDAQ listing Management team with a track
Slide 4: Our Pipeline
OUR PIPELINE Diverse, clinical-stage pipeline of candidates with great potential and a head start, honed into first- and best-in-class oncology medicines. PRODUCT / TYPE DISCOVERY PRECLINICAL PHASE IA/B PATENT LIFE L-DOS47 2036 Tumor microenvironment Non-Small Cell Lung Cancer (NSCLC) + extensions T
Slide 5: Lead Indications
LEAD INDICATIONS Prevalent and hard-to-treat cancers made vincible by novel therapies that rise to the challenge. HOW WE WANT TO MOVE THE NEEDLE LEAD INDICATIONS, GLOBAL INCIDENCE (MILLIONS) Lung cancer 2.5M ADD ≥30% EFFICACY to immune checkpoint inhibitors (ICIs) standard of care Breast cancer 2.3M
Slide 6: Investment & Return
INVESTMENT & RETURN USD 80M to achieve major project milestones and value inflection points for L-DOS47 and LEUMUNA as priority projects. USE OF PROCEEDS OVER THE NEXT 36 MONTHS THE WHOLE IS GREATER THAN THE SUM OF ITS PARTS CORPORATE CEACAM6 PLATFORM Grow world-class Phase IB + Phase II team random
Slide 7: Our Core Leadership & Scientific Team
OUR CORE Thomas Mehrling, MD, PhD Veronika Kandziora Rohit Babbar, CPA, CA Davide Guggi, PhD LEADERSHIP Chief Executive Officer Chief Operating Officer Chief Financial Officer Chief Technology Officer & SCIENTIFIC TEAM Jonathan Davis, PhD Brenda Lee, PhD Kim Gaspar, Jessica Kourniaktis, DPhil Direct
Slide 8: L-DOS47
L-DOS47 A first-in-class, clinical-stage antibody-enzyme conjugate (AEC) delivering a game-changing assist to anti-tumor immunity and blockbuster cancer immunotherapies. 8
Slide 9: The Problem: Tumor Acidosis
THE PROBLEM TUMOR ACIDOSIS The success of immune checkpoint inhibitors (ICIs) 70% of cancer patients don’t respond to immunotherapy.1 depends on the availability of functioning immune cells to mobilize against the tumor. But in the acidic microenvironment of solid Immunologically “cold” The acidic t
Slide 10: The Solution: L-DOS47
THE SOLUTION TUMOR DEFENCE BREAKER™ Camelid nanobodies High binding affinity to L-DOS47 CEACAM6. Urease enzyme A first-in-class AEC that neutralizes the Catalyzes urea breakdown into ammonia and CO₂, neutralizing acidic pH of the TME, helping turn the pH of the TME. immunologically cold tumors “hot”
Slide 11: Mechanism of Action
MECHANISM OF ACTION T Cells A HALLMARK OF CANCER The TME is acidic. TME acidosis leads to: Immunotherapy L-DOS47 Immunosuppression (“cold” tumors) Resistance to treatment neutralizes tumor acidity, Cancer proliferation taking the brakes off anti-tumor Chemotherapy Metastasis immunity and delivering
Slide 12: A Force Multiplier for Anti-PD-1 Antibodies
A FORCE MULTIPLIER FOR ANTI-PD-1 ANTIBODIES Pembrolizumab + L-DOS47 synergistically and significantly reduces tumor growth, volume and weight compared to pembrolizumab alone in 28 days in pancreatic cancer mouse models. -70% greater tumor volume reduction -50% greater tumor weight reduction with L-D
Slide 13: Clinically Safe and Effective with Chemo
CLINICALLY SAFE AND EFFECTIVE WITH CHEMO L-DOS47 in combination with Pemetrexed/Carboplatin delivers 75% overall clinical benefit in a Phase IB, open-label dose-escalation study in heavily pre-treated patients with Stage IV NSCLC. EFFICACY & SAFETY — Best % Change in Lesion Size from Baseline (patie
Slide 14: Timely & Close to the Finish Line
TIMELY & CLOSE TO THE FINISH LINE L-DOS47 STRENGTHS L-DOS47 OPPORTUNITIES L-DOS47 NEXT STEPS 2026 2027 2028 2029 2030 2031 First-in-class TME AEC Significant improvement in PFS Phase Ib completed Significant improvement in OS CMC clinical batch Results highly encouraging ICI market share expansion “
Slide 15: The Bigger Picture: CEACAM6
THE BIGGER PICTURE CEACAM6 CEACAM6 (carcinoembryonic antigen-related cell Overexpressed in major cancers adhesion 6) is a cell-surface protein overexpressed CEACAM6 is significantly on hard-to-treat solid tumors and a highly low in healthy tissue. promising target for antibody-based therapies.1 Heli
Slide 16: Leveraging Radio-Ligand Technology in Discovery
PRODUCT 2, CEACAM6 PLATFORM CEACAM6 Product 2 LEVERAGING RADIO- CEACAM6-RL-PDAC (radio-ligand targeting CEACAM6-expressing pancreatic adenocarcinoma). LIGAND TECHNOLOGY IN DISCOVERY Design Radio-Isotope Single chain camelid nanobody Alpha emitter, carefully with CEACAM6 high binding selected to maxi
Slide 17: The Promise of Our Discovery ADCs
CEACAM6 Products 3 & 4 Conjugation PRODUCTS 3 & 4, CEACAM6 PLATFORM CEACAM6-GIT (Gastrointestinal) Newest linker system, THE PROMISE OF OUR CEACAM6-GYN (Gynecological) ensuring systemic stability. DISCOVERY ADCs Carefully-designed ADCs capitalising on latest, state-of-the- art technology. Design Pay
Slide 18: LEUMUNA
LEUMUNA™ An oral immune checkpoint modulator to bring long-term remission within reach for patients relapsing with leukemia. 18
Slide 19: The Problem: Leukemia Relapse
THE PROBLEM LEUKEMIA RELAPSE More than 60,000 Allogeneic stem cell transplantation (allo-SCT) patients undergo allo-SCT each offers a potentially life-saving treatment for year.1 patients with hematological malignancies. But nothing is more devastating than seeing the Up to 30% or 18,000 Survival: ~
Slide 20: The Solution: LEUMUNA
THE SOLUTION Activated T-Cells LEUMUNA™ A pre-IND, first-in-class oral immune checkpoint modulator and inhibitor of PNP to initiate graft- Activates transplanted versus-leukemia (GvL) effect in patients immune system to fight relapsing with leukemia after allogeneic SCT. resurging leukemia GvL is th
Slide 21: Evidence with LEUMUNA
EVIDENCE WITH LEUMUNA LEUMUNA significantly reduces risk of relapse mortality in preclinical minor-MHC mismatch B Cell Acute leukemia model. 1) Improvement in survival with LEUMUNA is due to T-cell OVERALL SURVIVAL 2) Risk of graft-versus-host disease (GVHD) mortality outweighed by COMPETING RISK AN
Slide 22: Historical Clinical Data
HISTORICAL CLINICAL DATA Predecessor compound, Ulodesine (BCX4208), developed in gout and psoriasis, and analog, forodesine hydrochloride. BCX4208: OUTSTANDING SAFETY AND TOLERABILITY COMPLETE REMISSION ACHIEVED A 3-year old pediatric patient was cured of relapsed T-Cell Acute Demonstrated in Phase
Slide 23: LEUMUNA Facts & Prospects
LEUMUNA FACTS & PROSPECTS LEUMUNA STRENGTHS LEUMUNA OPPORTUNITIES LEUMUNA NEXT STEPS 2026 2027 2028 2029 2030 FDA Orphan status Potential 2+ yrs. OS or cure CoM Patent (exp. 2041) Poised to become SoC CMC clinical batch Breakthrough potential and Supporting clinical evidence accelerated approval IND
Slide 24: GEMCEDA
GEMCEDA™ A first-in-class oral gemcitabine to enrich the spectrum of disease-limiting and life- enhancing outcomes for patients whose cancer has progressed. 24
Slide 25: The Problem: Oral Gemcitabine
THE PROBLEM ORAL GEMCITABINE More than 30% Gemcitabine is a WHO-designated Essential of the 900 chemotherapy agents in development are oral agents, to Medicine used to treat one-third of all cancers improve access to care.2 and is among the most widely prescribed therapies worldwide.1 But with intra
Slide 26: GEMCEDA
GEMCEDA A pre-IND, first-in-class oral gemcitabine prodrug combined with cedazuridine, with bioavailability on par with IV (90%), for metronomic therapy to control tumor growth and preserve quality of life. 26
Slide 27: Gemcitabine Oral Chemotherapy
High-grade Serous High vs low replication stress (RB1, CDKN2A Ovarian Cancer* loss, or surplus of CCNE1, KRAS, MYC). Combination with PARP or ATR inhibitor. GEMCITABINE ORAL Pancreatic Ductal Use GemciTest ®️ to predict gemcitabine CHEMOTHERAPY Adenocarcinoma response. Target indications with biomar
Slide 28: GEMCEDA Facts & Prospects
GEMCEDA FACTS & PROSPECTS GEMCEDA STRENGTHS GEMCEDA OPPORTUNITIES GEMCEDA NEXT STEPS 2026 2027 2028 2029 2030 First-in-class oral gemcitabine IV gem. treats 1/3 of cancers Oral bioavailability ≈ IV Regulatory 505(b)2 pathway Tox & CMC clinical batch CoM Patent (exp. 2043) Maintenance therapy IND Est
Slide 29: The Bottom Line
THE BOTTOM LINE 29
Slide 30: Our Strategy
OUR STRATEGY Innovating from strength to shape a near future where hard-to-treat cancers are vincible. CANDIDATE L-DOS47 LEUMUNA™ GEMCEDA™ C6 RDCs & ADCs HARD-TO-TREAT Non-small cell lung Advanced solid Leukemia relapse Solid tumors CANCER cancer (NSCLC) tumors Synergistic efficacy with Backed by cl
Slide 31: Upcoming Milestones
Q1 2026 Q2 2026 Q3 2026 Q4 2026 Q1 2027 Q2 2027 UPCOMING Bridge financing (USD 25M) MILESTONES Relocation to US & NASDAQ listing FDA Meeting Our ambitious plan on our priority projects over the next 18 months. Public Offering (USD 80M) FPI (NSCLC in comb. with ICI) Financial / Corporate Milestone IN
Slide 32: Expert Collaborators' Opinions
EXPERT COLLABORATORS’ OPINIONS on Helix BioPharma’s most advanced assets. Professor Robert Gillies, Moffitt Cancer Center Vice-Chair Radiology, Director Professor Caius Radu, Departments of Molecular and Medical of Experimental Imaging Program & US Key Opinion Leader, on L-DOS47 Pharmacology and Sur
Slide 33: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation document contains certain forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Forward-looking statements are statements and information that are not historical facts but
Slide 34: Helix BioPharma contact
HELIX biopharma Shaping a near future where today’s hard-to-treat cancers are vincible. For investor relations, contact corporate@helixbiopharma.com HELIX BIOPHARMA CORP. Bay Adelaide Centre – North Tower 40 Temperance Street, Suite 2 Toronto, ON M5H 0B4 Tel: +1 857 208 7687 TSX: HBP Thomas Mehrling
Helix BioPharma — Investor Presentation (January 2026) on 6ix